IMV Inc.

  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Scientific & Clinical Advisors
    • Partnerships
  • The DPX Platform
    • Overview
    • Scientific Publications & Posters
  • Clinical Pipeline
    • Overview
    • Maveropepimut-S
    • DPX-RSV
    • DPX-COVID-19
    • Clinical Trials
  • News & Events
    • Press Releases
    • Events
    • Email Alerts
  • Investors
    • Overview
    • Press Releases
    • Events, Webcasts & Presentations
    • Financial Info
    • Stock Data
    • Filings
    • Governance
    • Contact Us
    • FAQ
  • Careers
    • Overview
    • Life at IMV
  • Contact

Press Releases

Investors

Investors

  • Overview
  • Press Releases
  • Events, Webcasts & Presentations
    • Overview
    • Presentations
    • Scientific Publications & Posters
    • Email Alerts
  • Financial Info
    • Financial Results
    • Tax Info
    • Proxy Info
    • Stock Option Plan
    • Deferred Share Unit Plan
  • Stock Data
    • NASDAQ: IMV
    • TSX: IMV
    • Analyst Coverage
  • Filings
    • SEC Filings
    • SEDAR
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Contact Us
  • FAQ
Mar 01, 2019 10:02am EST

IMV Inc. Announces Pricing of Public Offering

Feb 28, 2019 4:51pm EST

IMV Inc. Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares

Jan 29, 2019 7:05am EST

IMV Announces Clinical Update for DPX-Survivac Program in Ovarian Cancer Following Positive Feedback from U.S. FDA

Jan 28, 2019 4:35pm EST

IMV to Present at 2019 BIO CEO & Investor Conference

Jan 17, 2019 7:05am EST

First Patient Dosed in Phase 1 Clinical Trial Evaluating Neoepitopes Formulated in IMV’s DPX Delivery Platform in Ovarian Cancer Patients

Dec 13, 2018 4:05am EST

IMV Inc. Presents Updated Positive Data From Phase 1b/2 Combination Clinical Trial in Advanced Ovarian Cancer at 2018 ESMO Immuno-Oncology Congress

Dec 10, 2018 7:05am EST

IMV Announces Updated Clinical Data Presentation for Lead Candidate DPX-Survivac’s Phase 1b/2 Immunotherapy Combination Trial at the ESMO Immuno-Oncology Congress 2018

Dec 05, 2018 7:05am EST

IMV Welcomes Marc Jasmin as Senior Director, Investor Relations and Communications

Nov 26, 2018 4:35pm EST

IMV Leadership to Present Respiratory Syncytial Virus (RSV) Research at RespiDART 2018

Nov 20, 2018 7:05am EST

IMV Moves to Develop DPX-Survivac as Monotherapy for Recurrent Ovarian Cancer

RSS
  • Prev
  • 1...
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • ...36
  • Next
  • Email Alerts
  • Contacts
  • RSS News Feed
IMV Inc.
About Us The DPX Platform Clinical Pipeline News & Events Investors Careers Contact
Twitter LinkedIn Youtube
© 2021 IMV Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap